Pfizer takeover could delay drug development, says Astra chief

 

AstraZeneca Chief Executive Pascal Soriot: "The risk associated with any large merger is disruption"

Related Stories

The chief executive of AstraZeneca has warned that new drug development could be hit if it were taken over by Pfizer.

Pascal Soriot told MPs that a takeover would create huge disruption and distraction as scientists worried about their futures rather than development.

However, Business Secretary Vince Cable later told the Business Committee that blocking a bid could be "tricky".

The committee is taking evidence on the proposed takeover amid worries about the damage it could do to UK interests.

Earlier, Pfizer's chief Ian Read told the MPs that his company was not a ruthless cost-cutter, and said the drugmaker acted with "integrity".

He repeated assurances that Pfizer would protect jobs and investment, but admitted that a merger would mean a reduction in the combined companies' spending on research and development.

Uncertainty

Even though no formal offer from US-based Pfizer has been tabled, the proposed £63bn-plus takeover has generated huge controversy. The Commons Science Committee will hold its own hearing on Wednesday.

Mr Soriot told the Business Committee that the uncertainty created by a takeover could undermine some of AstraZeneca's work.

Start Quote

We are a highly ethical company. Pfizer is a company that keeps its promises”

End Quote Ian Read Chief executive, Pfizer

"Any distractions on work we are doing now could run the risk of delaying our drugs pipeline," he said. "From the lab to the patient takes many years.

"What will we tell the person whose father died from lung cancer because one of our medicines was delayed because our companies were involved in saving taxes or saving costs?

"It is logical to assume that a merger like this could mean substantial cost savings, and cost savings could mean job losses," he said.

Mr Soriot said the re-domiciling of the newly-merged company to the UK - which Pfizer has said would still see its headquarters remain in New York - would cause "substantial controversy", likely to result in delays.

However, he said that it would be the board of Astra's duty to consider a formal offer from Pfizer, despite rebuffing the US drugmaker's approaches so far.

Chief executive of Pfizer Ian Read: "I think the commitment of 20% of a global company's R&D in the UK is an unprecedented commitment"

"It's impossible to say we would never accept any offer," he told a committee. "We are very well aware of our fiduciary duty."

Limited powers

However, despite demands that the government should either block the bid or secure legal guarantees on jobs and investment, Mr Cable told the committee that intervention was "tricky".

The UK has public interest laws governing certain takeovers, such as those involving defence and media interests, but not for science.

Mr Cable said: "The framework which we have under the act, as you know, confines the public interest test quite narrowly and, of course, all of that takes place within the framework of European merger law."

For anyone in the pharmaceutical industry, the Holy Grail is the discovery of what they call a new "molecule", a cleverly-designed compound that proves effective as a treatment.

But achieving this is fiendishly complicated - getting approval has become hugely expensive and success is far from guaranteed.

AstraZeneca itself has a long history of developing new molecules to tackle everything from high blood pressure to breast cancer and the UK scientific community is rightly proud of that.

But less obvious amid the current war of words is that four of the company's most promising drugs are in its hands, not because of homegrown research, but because AstraZeneca acquired them when it bought a US firm called MedImmune.

One of these drugs is MEDI4736, not a name that trips off the tongue, but this molecule, designed to fight lung cancer, will soon enter the final phase of clinical trials.

So if Pfizer's takeover is successful, MEDI4736 will have yet another new owner.

No surprise, the staff of MedImmune - and the politicians supporting them in Maryland - are as worried about the implications of the Pfizer bid as AstraZeneca's people are here in the UK.

The business secretary refused to be drawn on the precise legal and financial mechanisms that could make Pfizer's assurances binding. He said he would "rather not expose" the government's thinking on that "in too much detail".

But he accepted that the government faced a "dilemma" between being open to the benefits of foreign investment and protecting wider national interests.

In response, Labour's shadow business secretary, Chuka Umunna, said he was still to be convinced that an acquisition would be good for the UK.

"I think what we heard at the hearing today reinforces the grave concerns we have about this deal and confirms many of the worst fears of many in the business and science community in the UK," he said.

"What do we know? [Pfizer] confirmed that they will be cutting jobs, they've confirmed that there will be a cut in the spending of the combined merged entity, they've confirmed that the business, AstraZeneca, will be split up, and they haven't ruled out selling off parts of it in the future."

And he pointed to AstraZeneca's assertion that the distraction of any deal could potentially inhibit the production of life-saving drugs.

But business body the Institute of Directors, said "we should be alive to the consequences of mounting a British Inquisition for those who wish to do business in what is supposed to be an open economy".

"If our politicians really want to whip up a storm around this issue, they'd be better off scrutinising the role of institutional investors in the whole process," added the body's director general Simon Walker.

"In particular, the asset managers and asset owners that control so many of AstraZeneca's shares."

Vince Cable says Pfizer faces "hurdles" before the takeover becomes binding

Earlier, Mr Read mounted a strong defence of Pfizer's record, rejecting complaints that it had a poor track record on maintaining jobs and investments, both in the UK and elsewhere.

Adrian Bailey, chairman of the Business Committee, asked Mr Read to respond to claims that Pfizer was like a "praying mantis" and a "shark that needs feeding".

Mr Read said he was "very proud" of his 35 years at the firm, describing it as a "company of high integrity focused on patients and delivering drugs to patients".

He said he was not concerned about an attack on the company by Swedish Prime Minister Fredrik Reinfeldt, who referred to "negative experiences" after Pfizer took over Pharmacia.

Mr Read said the comments were based on a "misunderstanding of the facts" over strategy and a promise to build a factory only if a product got regulatory approval. "Having set the facts right, I'm not concerned" by the comments, he said.

He added that a merged Pfizer-Astra would mean research expenditure would be lower than that of the two separate companies. This, he said, was because one of the drivers of the proposed deal was to increase efficiency in order to keep both firms competitive in an increasingly tough marketplace.

"Our commitment is to base 20% of our global research and development in the UK," he said. But without more due diligence on AstraZeneca's books "I can't tell you today how many people we are going to have in R&D," he added.

But the final jobs number would be "substantial", Mr Read promised. "I have not seen AstraZeneca's books. Some things are sight-unseen. But the numbers will be substantial... We are a highly ethical company. Pfizer is a company that keeps its promises."

Pfizer logo Pfizer has outlined its takeover proposals to AstraZeneca's shareholders

Committee member Mike Crockart asked why the UK Government should support a Pfizer bid, when "you have a reputation of being ruthless cost-cutters, and that seems to be borne out by what you have said today".

Mr Read replied that the takeover was "an opportunity to domicile the largest pharmaceutical company in the world, to bring the strength of the combined portfolios and to bring our financial strength into the UK and globally.

"I think it will strengthen the scientific base in the UK, a company our size making these sorts of commitments."

'Not long enough'

Before the committee hearing, the President of the Royal Society, Prof Sir Paul Nurse, told the BBC that Pfizer's five-year commitment to maintain research and jobs was "vague" and insufficient.

Sir Paul, who has submitted written evidence to the committee, said: "Research is a long-term business. I have researched for 40 years of my life. I know that five years is not long enough term to be committed to.

"They need to look at a 10-year horizon at least if they are actually going to make an important impact on this area and produce the medicines that will help people."

On Tuesday, Pfizer turned up the pressure on AstraZeneca by outlining its takeover proposals to Astra's shareholders.

Pfizer laid out the "strong strategic rationale" of the £63bn takeover plan.

Astra responded by calling Pfizer's takeover plan an "opportunistic attempt" to buy the company for a price that did not reflect the value of its "exciting pipeline" of new drugs.

Any deal would be the largest foreign takeover of a UK firm to date, but the proposal has revived memories of when US food giant Kraft abandoned jobs pledges after it bought Cadbury.

graphic about company size
 

More on This Story

Related Stories

Comments

This entry is now closed for comments

Jump to comments pagination
 
  • rate this
    +21

    Comment number 683.

    I worked for a company that merged with another. It was a complete disaster. I totally appreciate what the CEO of AstraZeneca was saying about disruption to the business.

  • rate this
    +25

    Comment number 660.

    My guess is that a large proportion of the people in this country are stakeholders in AZ through pension and other savings schemes. So they all have a valid opinion. Do they want to see R&D (=skilled workers) possibly move from this country and fewer companies (=less competition) supplying drugs to the NHS? Capitalism needs to benefit the whole country not just a single company.

  • rate this
    +22

    Comment number 624.

    It is obvious from some comments that the sole criteria for a takeover is making a quick buck. When UK no longer makes anything of significance where will investors go? Will major retail and insurance produce enough profit to suit more investors? If the purpose of investment is a quick buck rather than any sense of a long term strategy then the future for UK business is bleak.

  • rate this
    -76

    Comment number 105.

    there's a huge contradiction from the left on this. The left generally hate big business and hate pharmaceutical companies who they see as profiting from sick people. fair enough. but then you cant complain when the industry is driven down a path where R&D costs so much and new medicines don't get adopted by the NHS. job losses / mergers are inevitable

  • rate this
    +28

    Comment number 62.

    Either so many British businesses are badly mismanaged & unfit to survive, meaining takeovers are inevitable, or we have worthwhile industries needing proper managment & investment. The latter means there are still viable industries = proper employment for Brits, or the UK just goes to the wall & there's nothing left but shop work & fruit & veg picking. You choose.

 

Comments 5 of 10

 

More Business stories

RSS

BBC Business Live

  1.  
    PADDY POWER 07:26:
    Paddy Power pic from website

    Betting giant Paddy Power says pre-tax profits are down 13% at £62m for the first half of the year. The company says many football punters had "dream weekends" in January and March, with 16 and then 17 teams of the 21 most backed winning. "This proved costlier than John Cleese's divorce", says Paddy.

     
  2.  
    HAYS RESULTS 07:16:

    Profits have risen at the recruitment business Hays, which operates in 33 countries. Profits rose 12% in the past year to £132m. Dividends are up 5%. "In many of our global markets, the vast majority of professional and skilled recruitment is still done in-house, with minimal outsourcing to recruitment agencies which presents substantial long-term structural growth opportunities," the company said.

     
  3.  
    LIVING WAGE 07:05: BBC Radio 4

    On the TUC Living Wage story: TUC general secretary Frances O'Grady tells Today that women come off worse because there is low value attached to the jobs women tend to do, such as care working and shop work.

     
  4.  
    LIVING WAGE 06:53: BBC Radio 4
    Care worker

    Today is discussing the Living Wage concept. In many parts of Britain, women working part-time earn less than the Living Wage, says the TUC. Three quarters of part-time women workers in Lancashire do, as do two thirds of part-time women workers in West Somerset. TUC chief Frances O'Grady explains: "The minimum wage is an absolute floor, the Living Wage is the level that means you can take your children on holiday for a week - nothing fancy." The minimum wage is £6.31.

     
  5.  
    QANTAS 06:42:

    Can Qantas solve its huge financial problems? The BBC's Phil Mercer in Sydney says: "The airline's annual accounts have become a horror story of decline as it tries to chart a path back to profit and sustainability". Read more.

     
  6.  
    MALAYSIA AIRLINES 06:32: BBC Radio 4

    Can an airline survive two major plane disasters in a single year? Today says that's the question for Malaysia Airlines. Those who have flown on the airline recently report near empty cabins. Can Malaysian Airlines survive? David Learmount from Flightglobal thinks so. "Malaysia will be given a chance by the government and it will be given some money. People don't like seeing airlines go bust," he told Today listeners.

     
  7.  
    BUSINESS LENDING 06:22: Radio 5 live

    Wake Up to Money looks forward to later this morning when the Bank of England will give us an update on its Funding for Lending scheme - introduced two years ago to encourage banks to lend to small businesses. It's not been a rip-roaring success: a previous report said, despite all that help, the amount of money being lent was down £2.7bn over the first three months of this year.

     
  8.  
    QANTAS 06:12:
    A Qantas Airline plane gets takes off at Sydney Airport in Sydney on August 28, 2014

    Overnight Australia's national airline Qantas reported a huge loss of A$2.8bn for the past year - its biggest ever. That was partly due to writing down the value of its planes by A$2.6bn. Qantas added weak domestic demand, poor consumer spending and rising fuel costs also contributed. Chief executive Alan Joyce tried to put some gloss on the figures: "There is no doubt today's numbers are confronting... but they represent the year that is past".

     
  9.  
    SCOTTISH INDEPENDENCE 06:03:
    Saltire

    Pro-independence business people in Scotland have hit back. 200 of them have signed a letter, appearing in the Herald online, saying that the business case for independence "has been made - and it's strong and ambitious". They add: "The real threat to Scotland is the real possibility of a British exit from the European common market".

     
  10.  
    Rebecca Marston Business reporter, BBC News

    The monitor has been fitted and off we go. You can plug in to us bizlive@bbc.co.uk or @bbcbusiness. Here until 13:00.

     
  11.  
    06:00: Ian Pollock Business reporter, BBC News

    Good morning, the Business Live page will have its finger on the business pulse, just for you.

     

Features

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.